title: Participant survey results from the Starting Hizentra Administration with Resources and Education (SHARE) program.
abstract: Increased use of specialized infusion therapies has necessitated training of health care providers and patients. The Starting Hizentra Administration with Resources and Education (SHARE) program provided 709 US participants with information to educate patients with primary immunodeficiency disease (PIDD) on self-administration of 20% subcutaneous immunoglobulin (SCIG). Postprogram surveys assessed participants' experience and opinion of 20% SCIG. The most frequent questions about 20% SCIG regarded subcutaneous challenges (29%). Participants stated that all attributes of SCIG were beneficial (51%), and they expressed interest in future programs on non-PIDD diseases (26%). Survey results will assist in future SHARE and other relevant educational program optimization.
authors.affiliation: University of South Florida, Tampa, Florida (Ms Duff); and CSL Behring LLC, King of Prussia, Pennsylvania (Mss Riley, Zampelli, and Murphy). Carla Duff, MSN, CPNP, CCRP, is a pediatric nurse practitioner in the Division of Pediatric Allergy and Immunology at the University of South Florida/All Children's Hospital in St. Petersburg, Florida. She has many years of experience with clinical immunology and managing immunoglobulin replacement therapy for primary immunodeficient patients. Patty Riley, BAN, RN, CRNI®, is a medical science liaison in immunology for CSL Behring. She has three decades of clinical experience in adult critical care, neurology, and immunology. Annette Zampelli, MSN, CRNP, is a medical science liaison with CSL Behring with expertise in immunoglobulin therapies for over 20 years in the disease state areas of immunology, hematology-oncology, neurology, and transplant. Elyse Murphy, BSN, RN, is a medical science liaison with CSL Behring with expertise in immunoglobulin therapies for over 30 years in the disease state areas of immunology, hematology-oncology, neurology, and transplant.
authors.forename: Carla
authors.initials: C
authors.lastname: Duff
authors.forename: Patty
authors.initials: P
authors.lastname: Riley
authors.forename: Annette
authors.initials: A
authors.lastname: Zampelli
authors.forename: Elyse
authors.initials: E
authors.lastname: Murphy
mesh_terms: D006266:Health Education / Q000379:methods*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*; D055104:Infusions, Subcutaneous; D014481:United States
chemical_list: D016756:Immunoglobulins, Intravenous